Saved in:
| Title: | Fundamentals of Decentralized Clinical Trials Strategy and Execution / |
|---|---|
| From: |
edited by Anna H. Yang, Isaac R. Rodriguez-Chavez.
|
| Person: |
Yang, Anna H.
Rodriguez-Chavez, Isaac R. editor. |
| Corporate Author: | |
| Other Authors: | , |
| Format: | Electronic eBook |
| Language: | English |
| Published: |
Cham :
Springer Nature Switzerland : Imprint: Springer,
2024.
|
| Edition: | 1st ed. 2024. |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/978-3-031-62877-1 |
| Summary: | A timely and first-of-its-kind publication in the field, this short handbook on decentralized clinical trials (DCTs) offers a thorough exploration of the potential of DCTs to revolutionize clinical research through innovative approaches, including technology. This concise and easy-to-read publication is especially designed for those who seek to understand and get up-to-speed on what DCTs mean and how to work in this rapidly evolving field. As discussed in Chapter 1, DCTs address barriers to traditional trial participation, promoting accessibility, diversity, equity, and participant engagement. Chapter 2 examines how the COVID-19 pandemic and evolving regulations accelerated the adoption of DCTs, building on their application since the early 2000s. Chapters 3 and 4 highlight remaining operational complexities and the importance of careful trial design to ensure scientific rigor, operational feasibility, and compliance with regulations, ethics, data privacy, and participant safety. The book emphasizes the significance of the FDA's draft guidance on DCTs, detailing investigator responsibilities, local health care providers' use, and essential sponsor considerations. Chapter 5 stresses the need for clear metrics to evaluate DCT adoption's impact on recruitment, retention, diversity, safety, and cost efficiencies. Overall, this guide tracks DCT advancements and encourages readers to contribute to evidence-based integration, meeting participant expectations for convenience and fostering faster, more inclusive clinical studies. Ultimately, this book aims to support the transformation of modern clinical research, developing medical products more efficiently for those in need. A major contribution to the literature on clinical research, this work will be a resourceful tool to anyone interested in embracing decentralized clinical research and improving access and participation for all. |
| Physical Description: | 1 Online-Ressource (XVII, 83 p.) |
| ISBN: | 9783031628771 |
Staff View
MARC
| LEADER | 00000nam a22000005i 4500 | ||
|---|---|---|---|
| 001 | ZDB-2-SBL-978-3-031-62877-1 | ||
| 003 | DE-He213 | ||
| 005 | 20241107172737.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 241016s2024 sz | o |||| 0|eng d | ||
| 020 | |a 9783031628771 |9 978-3-031-62877-1 | ||
| 024 | 7 | |a 10.1007/978-3-031-62877-1 |2 doi | |
| 050 | 4 | |a RM300-666 | |
| 072 | 7 | |a MMG |2 bicssc | |
| 072 | 7 | |a MED071000 |2 bisacsh | |
| 072 | 7 | |a MKG |2 thema | |
| 082 | 7 | |a 615 |2 23 | |
| 245 | 1 | 0 | |a Fundamentals of Decentralized Clinical Trials |h [electronic resource] : |b Strategy and Execution / |c edited by Anna H. Yang, Isaac R. Rodriguez-Chavez. |
| 250 | |a 1st ed. 2024. | ||
| 264 | 1 | |a Cham : |b Springer Nature Switzerland : |b Imprint: Springer, |c 2024. | |
| 300 | |a 1 Online-Ressource (XVII, 83 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 347 | |a text file |b PDF |2 rda | ||
| 505 | 0 | |a 1. Introduction and overview of decentralized clinical trials -- 2. Technology landscape and requirements -- 3. Regulatory landscape -- 4. Methodology and protocol development -- 5. Goals and metrics of success. | |
| 520 | |a A timely and first-of-its-kind publication in the field, this short handbook on decentralized clinical trials (DCTs) offers a thorough exploration of the potential of DCTs to revolutionize clinical research through innovative approaches, including technology. This concise and easy-to-read publication is especially designed for those who seek to understand and get up-to-speed on what DCTs mean and how to work in this rapidly evolving field. As discussed in Chapter 1, DCTs address barriers to traditional trial participation, promoting accessibility, diversity, equity, and participant engagement. Chapter 2 examines how the COVID-19 pandemic and evolving regulations accelerated the adoption of DCTs, building on their application since the early 2000s. Chapters 3 and 4 highlight remaining operational complexities and the importance of careful trial design to ensure scientific rigor, operational feasibility, and compliance with regulations, ethics, data privacy, and participant safety. The book emphasizes the significance of the FDA's draft guidance on DCTs, detailing investigator responsibilities, local health care providers' use, and essential sponsor considerations. Chapter 5 stresses the need for clear metrics to evaluate DCT adoption's impact on recruitment, retention, diversity, safety, and cost efficiencies. Overall, this guide tracks DCT advancements and encourages readers to contribute to evidence-based integration, meeting participant expectations for convenience and fostering faster, more inclusive clinical studies. Ultimately, this book aims to support the transformation of modern clinical research, developing medical products more efficiently for those in need. A major contribution to the literature on clinical research, this work will be a resourceful tool to anyone interested in embracing decentralized clinical research and improving access and participation for all. | ||
| 650 | 0 | |a Pharmacology. | |
| 650 | 0 | |a Clinical medicine |x Research. | |
| 650 | 0 | |a Medicine |x Research. | |
| 650 | 0 | |a Biology |x Research. | |
| 650 | 0 | |a Pharmacovigilance. | |
| 650 | 0 | |a Therapeutics. | |
| 650 | 1 | 4 | |a Pharmacology. |
| 650 | 2 | 4 | |a Clinical Research. |
| 650 | 2 | 4 | |a Biomedical Research. |
| 650 | 2 | 4 | |a Drug Safety and Pharmacovigilance. |
| 650 | 2 | 4 | |a Therapeutics. |
| 700 | 1 | |a Yang, Anna H. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 700 | 1 | |a Rodriguez-Chavez, Isaac R. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 710 | 2 | |a SpringerLink (Online service) | |
| 773 | 0 | |t Springer Nature eBook | |
| 776 | 0 | 8 | |i Printed edition: |z 9783031628764 |
| 776 | 0 | 8 | |i Printed edition: |z 9783031628788 |
| 776 | 0 | 8 | |i Printed edition: |z 9783031628795 |
| 966 | 4 | 0 | |l DE-355 |p ZDB-2-SBL |q UBG_PDA_SBL |u https://doi.org/10.1007/978-3-031-62877-1 |3 Volltext |
| 912 | |a ZDB-2-SBL | ||
| 912 | |a ZDB-2-SXB | ||
| 950 | |a Biomedical and Life Sciences (SpringerNature-11642) | ||
| 950 | |a Biomedical and Life Sciences (R0) (SpringerNature-43708) | ||
| 912 | |a ZDB-2-SBL | ||
| 049 | |a DE-355 | ||
Record in the Search Index
| DE-BY-UBR_katkey | ZDB-2-SBL-978-3-031-62877-1 |
|---|---|
| _version_ | 1835726566887260160 |
| adam_text | |
| any_adam_object | |
| author2 | Yang, Anna H. Rodriguez-Chavez, Isaac R. |
| author2_role | edt edt |
| author2_variant | a h y ah ahy i r r c irr irrc |
| author_corporate | SpringerLink (Online service) |
| author_corporate_role | |
| author_facet | Yang, Anna H. Rodriguez-Chavez, Isaac R. SpringerLink (Online service) |
| building | Verbundindex |
| bvnumber | localUBR |
| callnumber-first | R - Medicine |
| callnumber-label | RM300-666 |
| callnumber-raw | RM300-666 |
| callnumber-search | RM300-666 |
| callnumber-sort | RM 3300 3666 |
| callnumber-subject | RM - Therapeutics and Pharmacology |
| collection | ZDB-2-SBL ZDB-2-SXB |
| contents | 1. Introduction and overview of decentralized clinical trials -- 2. Technology landscape and requirements -- 3. Regulatory landscape -- 4. Methodology and protocol development -- 5. Goals and metrics of success. |
| dewey-full | 615 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615 |
| dewey-search | 615 |
| dewey-sort | 3615 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| edition | 1st ed. 2024. |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04121nam a22005655i 4500</leader><controlfield tag="001">ZDB-2-SBL-978-3-031-62877-1</controlfield><controlfield tag="003">DE-He213</controlfield><controlfield tag="005">20241107172737.0</controlfield><controlfield tag="007">cr nn 008mamaa</controlfield><controlfield tag="008">241016s2024 sz | o |||| 0|eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783031628771</subfield><subfield code="9">978-3-031-62877-1</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/978-3-031-62877-1</subfield><subfield code="2">doi</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RM300-666</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MMG</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED071000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MKG</subfield><subfield code="2">thema</subfield></datafield><datafield tag="082" ind1="7" ind2=" "><subfield code="a">615</subfield><subfield code="2">23</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Fundamentals of Decentralized Clinical Trials</subfield><subfield code="h">[electronic resource] :</subfield><subfield code="b">Strategy and Execution /</subfield><subfield code="c">edited by Anna H. Yang, Isaac R. Rodriguez-Chavez.</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">1st ed. 2024.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Cham :</subfield><subfield code="b">Springer Nature Switzerland :</subfield><subfield code="b">Imprint: Springer,</subfield><subfield code="c">2024.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (XVII, 83 p.) </subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="347" ind1=" " ind2=" "><subfield code="a">text file</subfield><subfield code="b">PDF</subfield><subfield code="2">rda</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">1. Introduction and overview of decentralized clinical trials -- 2. Technology landscape and requirements -- 3. Regulatory landscape -- 4. Methodology and protocol development -- 5. Goals and metrics of success.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">A timely and first-of-its-kind publication in the field, this short handbook on decentralized clinical trials (DCTs) offers a thorough exploration of the potential of DCTs to revolutionize clinical research through innovative approaches, including technology. This concise and easy-to-read publication is especially designed for those who seek to understand and get up-to-speed on what DCTs mean and how to work in this rapidly evolving field. As discussed in Chapter 1, DCTs address barriers to traditional trial participation, promoting accessibility, diversity, equity, and participant engagement. Chapter 2 examines how the COVID-19 pandemic and evolving regulations accelerated the adoption of DCTs, building on their application since the early 2000s. Chapters 3 and 4 highlight remaining operational complexities and the importance of careful trial design to ensure scientific rigor, operational feasibility, and compliance with regulations, ethics, data privacy, and participant safety. The book emphasizes the significance of the FDA's draft guidance on DCTs, detailing investigator responsibilities, local health care providers' use, and essential sponsor considerations. Chapter 5 stresses the need for clear metrics to evaluate DCT adoption's impact on recruitment, retention, diversity, safety, and cost efficiencies. Overall, this guide tracks DCT advancements and encourages readers to contribute to evidence-based integration, meeting participant expectations for convenience and fostering faster, more inclusive clinical studies. Ultimately, this book aims to support the transformation of modern clinical research, developing medical products more efficiently for those in need. A major contribution to the literature on clinical research, this work will be a resourceful tool to anyone interested in embracing decentralized clinical research and improving access and participation for all.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Pharmacology.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Clinical medicine</subfield><subfield code="x">Research.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Medicine</subfield><subfield code="x">Research.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Biology</subfield><subfield code="x">Research.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Pharmacovigilance.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Therapeutics.</subfield></datafield><datafield tag="650" ind1="1" ind2="4"><subfield code="a">Pharmacology.</subfield></datafield><datafield tag="650" ind1="2" ind2="4"><subfield code="a">Clinical Research.</subfield></datafield><datafield tag="650" ind1="2" ind2="4"><subfield code="a">Biomedical Research.</subfield></datafield><datafield tag="650" ind1="2" ind2="4"><subfield code="a">Drug Safety and Pharmacovigilance.</subfield></datafield><datafield tag="650" ind1="2" ind2="4"><subfield code="a">Therapeutics.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yang, Anna H.</subfield><subfield code="e">editor.</subfield><subfield code="4">edt</subfield><subfield code="4">http://id.loc.gov/vocabulary/relators/edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rodriguez-Chavez, Isaac R.</subfield><subfield code="e">editor.</subfield><subfield code="4">edt</subfield><subfield code="4">http://id.loc.gov/vocabulary/relators/edt</subfield></datafield><datafield tag="710" ind1="2" ind2=" "><subfield code="a">SpringerLink (Online service)</subfield></datafield><datafield tag="773" ind1="0" ind2=" "><subfield code="t">Springer Nature eBook</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Printed edition:</subfield><subfield code="z">9783031628764</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Printed edition:</subfield><subfield code="z">9783031628788</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Printed edition:</subfield><subfield code="z">9783031628795</subfield></datafield><datafield tag="966" ind1="4" ind2="0"><subfield code="l">DE-355</subfield><subfield code="p">ZDB-2-SBL</subfield><subfield code="q">UBG_PDA_SBL</subfield><subfield code="u">https://doi.org/10.1007/978-3-031-62877-1</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SBL</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SXB</subfield></datafield><datafield tag="950" ind1=" " ind2=" "><subfield code="a">Biomedical and Life Sciences (SpringerNature-11642)</subfield></datafield><datafield tag="950" ind1=" " ind2=" "><subfield code="a">Biomedical and Life Sciences (R0) (SpringerNature-43708)</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SBL</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield></record></collection> |
| id | ZDB-2-SBL-978-3-031-62877-1 |
| illustrated | Not Illustrated |
| indexdate | 2025-06-23T13:27:58Z |
| institution | BVB |
| isbn | 9783031628771 |
| language | English |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | 1 Online-Ressource (XVII, 83 p.) |
| psigel | ZDB-2-SBL UBG_PDA_SBL ZDB-2-SBL ZDB-2-SXB |
| publishDate | 2024 |
| publishDateSearch | 2024 |
| publishDateSort | 2024 |
| publisher | Springer Nature Switzerland : Imprint: Springer, |
| record_format | marc |
| spelling | Fundamentals of Decentralized Clinical Trials [electronic resource] : Strategy and Execution / edited by Anna H. Yang, Isaac R. Rodriguez-Chavez. 1st ed. 2024. Cham : Springer Nature Switzerland : Imprint: Springer, 2024. 1 Online-Ressource (XVII, 83 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier text file PDF rda 1. Introduction and overview of decentralized clinical trials -- 2. Technology landscape and requirements -- 3. Regulatory landscape -- 4. Methodology and protocol development -- 5. Goals and metrics of success. A timely and first-of-its-kind publication in the field, this short handbook on decentralized clinical trials (DCTs) offers a thorough exploration of the potential of DCTs to revolutionize clinical research through innovative approaches, including technology. This concise and easy-to-read publication is especially designed for those who seek to understand and get up-to-speed on what DCTs mean and how to work in this rapidly evolving field. As discussed in Chapter 1, DCTs address barriers to traditional trial participation, promoting accessibility, diversity, equity, and participant engagement. Chapter 2 examines how the COVID-19 pandemic and evolving regulations accelerated the adoption of DCTs, building on their application since the early 2000s. Chapters 3 and 4 highlight remaining operational complexities and the importance of careful trial design to ensure scientific rigor, operational feasibility, and compliance with regulations, ethics, data privacy, and participant safety. The book emphasizes the significance of the FDA's draft guidance on DCTs, detailing investigator responsibilities, local health care providers' use, and essential sponsor considerations. Chapter 5 stresses the need for clear metrics to evaluate DCT adoption's impact on recruitment, retention, diversity, safety, and cost efficiencies. Overall, this guide tracks DCT advancements and encourages readers to contribute to evidence-based integration, meeting participant expectations for convenience and fostering faster, more inclusive clinical studies. Ultimately, this book aims to support the transformation of modern clinical research, developing medical products more efficiently for those in need. A major contribution to the literature on clinical research, this work will be a resourceful tool to anyone interested in embracing decentralized clinical research and improving access and participation for all. Pharmacology. Clinical medicine Research. Medicine Research. Biology Research. Pharmacovigilance. Therapeutics. Clinical Research. Biomedical Research. Drug Safety and Pharmacovigilance. Yang, Anna H. editor. edt http://id.loc.gov/vocabulary/relators/edt Rodriguez-Chavez, Isaac R. editor. edt http://id.loc.gov/vocabulary/relators/edt SpringerLink (Online service) Springer Nature eBook Printed edition: 9783031628764 Printed edition: 9783031628788 Printed edition: 9783031628795 |
| spellingShingle | Fundamentals of Decentralized Clinical Trials Strategy and Execution / 1. Introduction and overview of decentralized clinical trials -- 2. Technology landscape and requirements -- 3. Regulatory landscape -- 4. Methodology and protocol development -- 5. Goals and metrics of success. Pharmacology. Clinical medicine Research. Medicine Research. Biology Research. Pharmacovigilance. Therapeutics. Clinical Research. Biomedical Research. Drug Safety and Pharmacovigilance. |
| title | Fundamentals of Decentralized Clinical Trials Strategy and Execution / |
| title_auth | Fundamentals of Decentralized Clinical Trials Strategy and Execution / |
| title_exact_search | Fundamentals of Decentralized Clinical Trials Strategy and Execution / |
| title_full | Fundamentals of Decentralized Clinical Trials [electronic resource] : Strategy and Execution / edited by Anna H. Yang, Isaac R. Rodriguez-Chavez. |
| title_fullStr | Fundamentals of Decentralized Clinical Trials [electronic resource] : Strategy and Execution / edited by Anna H. Yang, Isaac R. Rodriguez-Chavez. |
| title_full_unstemmed | Fundamentals of Decentralized Clinical Trials [electronic resource] : Strategy and Execution / edited by Anna H. Yang, Isaac R. Rodriguez-Chavez. |
| title_short | Fundamentals of Decentralized Clinical Trials |
| title_sort | fundamentals of decentralized clinical trials strategy and execution |
| title_sub | Strategy and Execution / |
| topic | Pharmacology. Clinical medicine Research. Medicine Research. Biology Research. Pharmacovigilance. Therapeutics. Clinical Research. Biomedical Research. Drug Safety and Pharmacovigilance. |
| topic_facet | Pharmacology. Clinical medicine Research. Medicine Research. Biology Research. Pharmacovigilance. Therapeutics. Clinical Research. Biomedical Research. Drug Safety and Pharmacovigilance. |
| work_keys_str_mv | AT yangannah fundamentalsofdecentralizedclinicaltrialsstrategyandexecution AT rodriguezchavezisaacr fundamentalsofdecentralizedclinicaltrialsstrategyandexecution AT springerlinkonlineservice fundamentalsofdecentralizedclinicaltrialsstrategyandexecution |